• CXCR4–EGFR Heteromers Rewire Cancer Signaling

  2026-09-05

  Comez and colleagues show that CXCR4 and EGFR assemble into ligand-sensitive oligomeric signaling complexes rather than acting only as independent receptors. By combining NanoBRET with nanobody-based proximity ligation assays, the study links receptor proximity to altered Gi, PLCγ, and β-arrestin-2 coupling and validates the complexes in native HeLa cells.

• Novel PDK4 Inhibitors for Metabolic Disease

  2026-09-04

  The 2019 Journal of Medicinal Chemistry study identified compound 8c as an allosteric pyruvate dehydrogenase kinase 4 inhibitor with nanomolar in vitro activity and activity in mouse models of glucose intolerance and allergic reactions. Its combination of structure-based optimization, pharmacokinetic characterization, in vivo testing, and docking provides a useful framework for evaluating PDK4 as a multidisease drug-discovery target.

• Nigericin Sodium Salt for Ion Transport Assays

  2026-09-04

  Nigericin sodium salt provides a practical way to perturb K+/H+ exchange, cytoplasmic pH, and membrane ion gradients in controlled in vitro systems. This guide connects ionophore workflows with time-resolved cancer drug-response measurements, platelet aggregation modulation, and exploratory lead (Pb2+) ion transport studies.

• Neuromedin S (rat): Protocol and QC Guide

  2026-09-03

  Neuromedin S (rat) provides a defined peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling in rat-oriented research workflows. This guide covers preparation, storage, assay controls, and troubleshooting; it does not establish therapeutic, diagnostic, cross-species, or literature-validated dosing conditions.

• dKeap1–Lamin Dm0 and Nuclear Architecture

  2026-09-02

  Carlson and colleagues identify a functional interaction between Drosophila Keap1 and the B-type lamin Dm0, extending Keap1 biology beyond xenobiotic-responsive transcription. Their results connect dKeap1 misregulation with lamin redistribution, heterochromatin-marker spreading, nuclear-lamina defects, and developmental genetic interaction.

• CS-NAC Nanoparticles Suppress Ferroptosis in OA

  2026-09-02

  A 2025 Small Science study developed chondroitin sulfate-modified PLGA nanoparticles to deliver N-acetylcysteine directly to chondrocytes in osteoarthritis. The formulation sustained local antioxidant activity, maintained glutathione and GPX4 function, reduced ferroptosis, and protected cartilage more effectively than free NAC or nontargeted nanoparticles in a murine model.

• Epalrestat Activates KEAP1/Nrf2 in Parkinson’s Disease

  2026-09-02

  Jia et al. report that epalrestat, an established aldose reductase inhibitor, protects dopaminergic neurons in cellular and murine Parkinson’s disease models by reducing oxidative stress and mitochondrial dysfunction. The study’s main innovation is evidence that epalrestat directly interacts with KEAP1, promotes KEAP1 degradation, and activates Nrf2 signaling, while its translational relevance remains preclinical.

• Ibrexafungerp: From MIC to Model Design

  2026-09-01

  Ibrexafungerp and MK 3118 offer a distinctive route from glucan-synthase biology to practical antifungal assay design. This article explains how genotype-aware susceptibility testing, acidic-pH considerations, and animal models can improve translational interpretation.

• Ruxolitinib Phosphate: From JAK Blockade to Cell Fate

  2026-08-31

  Ruxolitinib phosphate (INCB018424) is more than a selective JAK1/JAK2 research inhibitor: it can connect cytokine signaling inhibition with mitochondrial and cell-death phenotypes. This assay-focused guide explains how to design, interpret, and translate experiments without overstating mechanistic evidence.

• Bazedoxifene Workflows for ER Signaling Research

  2026-08-31

  Build reproducible Bazedoxifene assays that connect ERα/ERβ binding, estrogen-responsive transcription, MCF7 proliferation, and bone-model endpoints. This workflow emphasizes concentration selection, tissue-context interpretation, and troubleshooting rather than treating a selective estrogen receptor modulator as a one-dimensional antagonist.

• FH1 Small Molecule for Mature iHeps

  2026-08-30

  FH1 supports a more functional hepatocyte-like cell (iHep) phenotype by combining stronger albumin output, higher CYP3A4 levels, improved morphology, and lower AFP secretion. This makes the FH1 small molecule useful for maturation workflows, metabolism assays, and carefully controlled liver research models rather than relying on a single marker.

• Acetylcysteine as a Redox Control in Cancer Assays

  2026-08-29

  Acetylcysteine can do more than suppress oxidative stress: it can function as a mechanistic control for separating redox effects from photothermal and immune-remodeling signals. This guide shows how to use N-acetyl-L-cysteine rigorously in cancer, hepatic, respiratory, and neurodegeneration research without overinterpreting antioxidant rescue.

• Roscovitine (Seliciclib, CYC202) Assay Guide

  2026-08-28

  A scenario-based guide to using Roscovitine (Seliciclib, CYC202), SKU A1723, in cell-cycle, viability, proliferation, and cytotoxicity workflows. It connects biochemical potency, solvent handling, reversible arrest, and vendor selection to practical strategies for more interpretable cancer biology research.

• Gap26 in 3D Osteocyte Calcium Signaling

  2026-08-28

  Gap26 turns a dynamic 3D osteocyte chip into a causal test of connexin 43–dependent calcium-wave propagation rather than a simple observation platform. This workflow pairs controlled peptide inhibition with pulsatile flow, live imaging, and endpoint validation to separate mechanotransduction from secondary viability or matrix effects.

• Syringin Targets EGFR/PI3K/Akt in RCC

  2026-08-28

  The reference study identifies syringin as a potential natural-product sensitizer for renal cell carcinoma (RCC), linking its antiproliferative and proapoptotic effects to EGFR/PI3K/Akt signaling. Its combined computational and in vitro design suggests a framework for investigating adjuncts to sunitinib, while the evidence remains preclinical and requires validation in more physiologically representative models.

8671 records 8/579 page Previous Next First page 上5页 678910 下5页 Last page